As the use of GLP-1 receptor agonists for weight management surges, a July 2026 Gallup poll revealed that 11 percent of US adults now use these medications, nearly quadrupling participation rates from 2024. According to obesity specialists, this widespread adoption has fueled widespread public anxiety over lean tissue loss, frequently amplified by viral social media terms such as “Ozempic face” and “Ozempic butt.” However, medical experts emphasize that a reduction in lean mass is a standard physiological consequence of any significant weight reduction and does not represent an isolated danger unique to GLP-1 therapies.
Understanding Lean Tissue Loss During Weight Reduction
According to Dr. Carol Eisenstat, an anesthesiologist and founder of the New Jersey-based medical weight loss program SlimMD, a decrease in lean body mass occurs naturally whenever a person loses a substantial amount of weight, whether through traditional dieting, bariatric surgery, or pharmaceutical interventions. Clinical studies indicate that roughly one-quarter to 40 percent of total weight lost during GLP-1 treatment can consist of lean mass. Obesity medicine physician Dr. Jessica Duncan explains that the vast majority of weight dropped on these medications is fat tissue, which frequently improves an individual’s overall fat-to-muscle ratio despite the concurrent drop in lean mass.
Differentiating Cosmetic Volume Loss from Clinical Muscle Atrophy
Public discussions often conflate visible aesthetic changes with actual muscular degeneration. Terms like “Ozempic face” describe a gaunt or hollow appearance caused by the loss of subcutaneous facial fat, while “Ozempic butt” stems from a reduction in fat deposits around the gluteal region. Eisenstat notes that these visual transformations create a false impression that the drugs actively strip away functional skeletal muscle, whereas patients are primarily shedding volume and fat stores. Duncan stresses that while genuine, clinically significant muscle loss demands medical attention, it remains a manageable hurdle rather than an inevitable outcome for the majority of patients.
High-Risk Patient Demographics and Protective Strategies
Certain patient populations face a higher vulnerability to adverse body composition shifts and require enhanced clinical oversight. Duncan identifies older adults experiencing age-related muscle and bone decline, postmenopausal women, individuals starting treatment with pre-existing low muscle mass, and patients undergoing rapid weight loss as groups needing rigorous monitoring. To safeguard muscle health, both specialists recommend prioritizing dietary protein intake and engaging in consistent resistance training. Eisenstat recommends at least two units of resistance training per week. Eisenstat points out that patients who deliberately integrate these two habits achieve significantly better results in preserving muscle than those who ignore them.
Emerging Pharmacological Solutions for Muscle Preservation
To address ongoing concerns regarding lean tissue depletion, pharmaceutical researchers are actively developing complementary therapies designed for co-administration with GLP-1 drugs. Among the most closely watched is apitegromab, an experimental treatment that demonstrated early clinical promise in helping patients preserve lean body mass while continuing to shed fat. Eisenstat notes that multiple investigative compounds now target muscle preservation as a primary clinical endpoint, a shift that is expected to redefine the clinical dialogue surrounding obesity treatment and body composition over the coming years.